Prognostic Factor Analysis in Metastatic Esophageal Squamous Cell Carcinoma
This study has been completed.
Information provided by (Responsible Party):
Jeeyun Lee, Samsung Medical Center
First received: November 11, 2011
Last updated: April 7, 2013
Last verified: April 2013
Esophageal squamous cell carcinoma is considerably more prevalent in East Asia. Despite of relatively high prevalence of esophageal SCC, prognosis is very poor with limited options of effective chemotherapy regimens. We attempted to identify favorable subgroups of patient who are likely to benefit from 5- fluorouracil/cisplatin(FP) or capecitabine/cisplatin (XP) chemotherapy as first-line treatment.Between January 2000 to December 2010, 239 patients were diagnosed of recurrent, metastatic esophageal SCC and received either FP or XP as first-line chemotherapy. Clinicopathologic variables and treatment outcome were retrospectively collected. we analysis treatment outcome of palliative chemotherapy in metastatic esophageal squamous cell carcinoma and make prognostic scoring system. The present study represents the largest series to analyze the treatment outcome of FP/XP chemotherapy in metastatic SCC. Risk-adapted stratification of treatment for subgroup of metastatic SCC patients should be actively pursued.
Metastatic Esophageal Squamous Cell Carcinoma
||Time Perspective: Retrospective
||Fluoropyrimidine/Platinum-based First-line Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma: Prognostic Factor Analysis in 239 Patients
Primary Outcome Measures:
- Overall Survival [ Time Frame: 12 month ] [ Designated as safety issue: Yes ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||December 2012 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Between January 2000 to December 2010, 239 patients were diagnosed of recurrent, metastatic esophageal SCC and received either FP or XP as first-line chemotherapy.
- recurrent, metastatic esophageal SCC
- received either FP or XP as first-line chemotherapy.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01472419
Samsung Medical Center
||Jeeyun Lee, M.D., Ph.D.
||Samsung Medical Center, Seoul, Korea
No publications provided
||Jeeyun Lee, Professor of Medicine, Sungkyunkwan University School of Medicine, Department of Hematology and Oncology, Samsung Medical Center
History of Changes
|Other Study ID Numbers:
|Study First Received:
||November 11, 2011
||April 7, 2013
||South Korea: Institutional Review Board
Keywords provided by Samsung Medical Center:
metastatic esophageal squamous cell carcinoma
Fluoropyrimidine/platinum-based first-line chemotherapy
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 20, 2014
Carcinoma, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell